The studies
Kisspeptin Research: The Mechanism and the Measured Human Data
From the ion channels that fire a GnRH neuron to the LH and testosterone numbers in healthy men — the record, organized by finding and cited to source.
Start here
Kisspeptin research answers one question in many ways: how does a brain-made peptide switch on the whole reproductive hormone system? The mechanism is now well mapped. Kisspeptin binds KISS1R (a receptor on the GnRH-releasing neurons of the hypothalamus), sets off a calcium signal inside those cells, and makes them fire and release GnRH in pulses [2]. GnRH then drives the pituitary to release LH and FSH, which drive the sex steroids.
The human studies measure that chain directly. Give kisspeptin to a healthy person and LH climbs first, FSH less, testosterone last [8]. The strongest single proof that this pathway is essential comes from genetics: when the receptor is broken, puberty never arrives [1]. From there the literature branches into men's hormone data, women's cycle restoration, IVF triggering, and a new non-injected route. Each branch is below, led by what it measured. None of these numbers is a dosing instruction — they are research readouts by population and route.
How kisspeptin fires a GnRH neuron
The mechanism is defined at the level of single cells. Kisspeptin (100 nM) depolarized GnRH neurons by 6 ± 1 mV and increased their firing rate by 87 ± 4% in about 75% of adult GnRH neurons; the response ran through a PLC–IP3-receptor–calcium cascade (phospholipase C, an enzyme that releases calcium stored inside the cell) that closed potassium channels and opened non-selective cation channels [2]. The result is depolarization — the electrical change that makes a neuron fire — and pulsatile GnRH release.
Upstream of this sit the KNDy neurons of the arcuate nucleus — cells co-expressing kisspeptin, neurokinin B and dynorphin — widely proposed as the GnRH pulse generator: neurokinin B starts a synchronized burst, dynorphin ends it, and kisspeptin relays the output to GnRH neurons. This is why kisspeptin's signature is a pulse, not a steady tone.
Genetics proved the pathway is essential
The foundational human finding is genetic. Loss-of-function mutations in GPR54 (KISS1R) caused autosomal-recessive idiopathic hypogonadotropic hypogonadism with failure of puberty, and Gpr54-knockout mice reproduced the phenotype — establishing kisspeptin–GPR54 signaling as essential for reproductive maturation [1]. In other words: no working receptor, no puberty.
The same logic runs the other way as a research probe. When exogenous kisspeptin is given to patients with idiopathic hypogonadotropic hypogonadism, those with an abiding defect fail to mount the LH response that the same bolus reliably triggers in healthy men — a readout of impaired GnRH-neuronal capacity [12]. And in children with delayed puberty, a kisspeptin challenge produces divergent LH responses, with a subset showing robust adult-like responses — informative about where each child's pubertal axis stands [11].
Kisspeptin-10
Kisspeptin-10 is the short 10-residue C-terminal fragment, and it is a potent LH stimulator in men. In healthy men, an intravenous kisspeptin-10 bolus produced maximal LH stimulation at 1 µg/kg, raising LH from 4.1 to 12.4 IU/L at 30 minutes; continuous infusion at 1.5 µg/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/h, while a higher 4 µg/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [3]. A direct head-to-head in healthy men found kisspeptin-10 and kisspeptin-54 produced comparable gonadotropin responses at matched infusion rates [10]. Kisspeptin-10's practical drawback is speed: its functional half-life is only about 4 minutes.
Kisspeptin-54
Kisspeptin-54 is the full 54-residue isoform — the form originally named metastin. In an early human study, intravenous kisspeptin-54 (4 pmol/kg/min for 90 min) raised mean 90-minute LH to 10.8 ± 1.5 versus 4.2 ± 0.5 U/L on saline in healthy men, with smaller rises in FSH and testosterone, and a measured plasma half-life of 27.6 ± 1.1 minutes [8] — roughly seven times longer than kisspeptin-10. That longer duration makes kisspeptin-54 the isoform of choice for the reproductive-medicine work below. In men with type 2 diabetes and mild biochemical hypogonadism, kisspeptin-10 still stimulated serum testosterone and LH, pointing to a central (hypothalamic) contribution to their low testosterone [9].
Restoring cycles, triggering ovulation, and a non-injected route
In women with hypothalamic amenorrhea, continuous intravenous kisspeptin-54 (0.01–1.00 nmol/kg/h) restored pulsatile LH secretion: LH pulses rose from 1.6 to 5.0 per 8 hours (~3-fold) and pulse secretory mass rose ~6-fold versus vehicle — though the highest dose produced tachyphylaxis over the infusion [4]. Kisspeptin and LH secretory events are temporally coupled in functional hypothalamic amenorrhea, consistent with kisspeptin output driving the residual pulses [15], and stress is thought to suppress reproduction largely by inhibiting kisspeptin neurons via CRH and glucocorticoids [14].
In IVF, a Phase 2 randomized trial of 60 women at high risk of OHSS used subcutaneous kisspeptin-54 (3.2–12.8 nmol/kg) to trigger oocyte maturation in 95% of women, with no case of moderate, severe or critical OHSS; the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [5]. Most recently, in 2025, intranasal kisspeptin-54 (12.8 nmol/kg) rapidly stimulated LH in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L) and women with hypothalamic amenorrhea (+4.4 IU/L) without adverse events, with the nasal formulation stable up to 60 days at 4 °C — the first demonstration of a non-invasive route [6].
The state of the evidence
A 2025 systematic review identified 29 interventional clinical trials (searched through February 2023) spanning secondary amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation, and noted considerably fewer side effects than comparators — while confirming that no kisspeptin product is regulatory-approved [7]. The honest summary: the mechanism is solid, the acute human readouts are reproducible, the safety profile in short studies is favorable, and the gaps are Phase 3 trials, long-term safety, and independent multi-centre replication. The KISS1 system is also context-dependent in cancer — anti-metastatic in most solid tumors [13] but potentially pro-tumorigenic in some settings — which is part of why this remains a research compound, not a product.